Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04799288|
Recruitment Status : Recruiting
First Posted : March 16, 2021
Last Update Posted : March 16, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a rare, progressive disease. It occurs in some people infected with the HTLV-1 virus. It leads to weakness in the lower limbs and other serious problems. It has no treatment. Teriflunomide is a drug used to treat multiple sclerosis. It reduces immune cells that make the disease worse. Researchers want to learn if this drug can help people with HAM/TSP.
To learn the effects, immune response, safety, and tolerability of teriflunomide in people with HAM/TSP.
Adults ages 18 and older with HAM/TSP.
Participants will be screened under protocol 98-N-0047.
Participants will have a medical history. They will have physical and neurological exams. They will have blood and urine tests.
Participants will take 1 tablet of the study drug once a day for 9 months. They will keep a drug diary.
Participants will have lymphapheresis. For this, blood is drawn from a needle in one arm. A machine divides the blood into red cells, plasma, and white cells. The white cells are removed. The plasma and red cells are returned to the participant through a needle in the other arm.
Participants will have lumbar punctures ( spinal taps ). For this, a thin needle is inserted into the spinal canal in the lower back. Spinal fluid is removed.
Participants will have magnetic resonance imaging (MRI) of the brain and spine. The MRI scanner is a metal cylinder surrounded by a strong magnetic field. During the MRI, participants will lie on a table that can slide in and out of the scanner.
Participation will last for 15 months.
|Condition or disease||Intervention/treatment||Phase|
|HAM/TSP||Drug: Teriflunomide||Phase 1 Phase 2|
In this single center, single arm, open label, baseline versus treatment pilot clinical trial, sixteen subjects with HAM/TSP will receive teriflunomide 14mg by mouth once a day in an initial 9 month treatment phase, followed by a 3 month post treatment follow-up phase. Outcome measures will be collected every 3 months for the duration of the study.
We will determine the effects of teriflunomide, an FDA approved drug for the treatment of relapsing remitting multiple sclerosis that inhibits de novo pyrimidine synthesis, on immune activation markers in patients with HAM/TSP and the correlation of these with virological, radiological and clinical measures of disease burden .
The primary outcome measure is ex vivo spontaneous lymphoproliferation in HAM/TSP patients receiving teriflunomide. Secondary outcome measures will include determination of immune activation patterns of PBMC and CSF using multicolor flow cytometric analysis and HTLV-I proviral load in blood and CSF. Safety and tolerability of teriflunomide will be assessed by tabulation of adverse events, clinical exam, standardized neurological disability scales (EDSS, IPEC, HAQ-DI), MR imaging of brain and spinal cord and clinical laboratory studies.
Up to 24 adults with HAM/TSP, targeting at least 16 participants who complete 9 months of treatment with teriflunomide
Description of Sites/Facilities Enrolling Participants:
NIH Clinical Center
Description of Study Intervention:
Administration of teriflunomide 14mg daily for 9 months
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||24 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I/II Study of Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis|
|Actual Study Start Date :||September 24, 2021|
|Estimated Primary Completion Date :||August 31, 2025|
|Estimated Study Completion Date :||August 31, 2025|
Teriflunomide 14 mg daily
Teriflunomide 14mg will be administered orally as 1 tablet once daily during the 9-month treatment phase of the study.
- ex vivo spontaneous lymphoproliferation in HAM/TSP patients receiving teriflunomide [ Time Frame: Percent change between Day 0 and month 9 of spontaneous proliferation. ]ex vivo spontaneous lymphoproliferation of HAM/TSP patients receiving teriflunomide and multicolor flow cytometric analysis of immune activation markers in both PBMCs and CSF
- Tabulation of adverse events [ Time Frame: at each visit ]This is a first in HAM/TSP pilot study using teriflunomide thus important to monitor for any unexpected events related to worsening of disease laboratory and clinical measures.
- Percent change between CD8+ and CD4+ cells in the CSF [ Time Frame: between month -3 and month 9 ]CD8 cells are thought to be immunopathogenic and drive the immune response. In vitro studies have shown a reduction of CD8+ and CD4+ cells in the presences of teriflunomide.
- HTLV-1 proviral load in the peripheral blood mononuclear cells (PBMCs) [ Time Frame: at month 9 and compared to Day 0 ]HTLV-1 proviral load is a measure of the percent of infected cells and previous data suggests a correlation with disease activity.
- HTLV-1 proviral load in the CSF cells [ Time Frame: at month 9 and compared to month -3 ]HTLV-1 proviral load is a measure of the percent of infected cells and previous data suggests a correlation with disease activity.
- Change in IPEC score [ Time Frame: at month 9 and compared to Day 0 ]This is a first in HAM/TSP pilot study using teriflunomide thus important to monitor for any unexpected events related to worsening of clinical measures.
- Change in EDSS score [ Time Frame: at month 9 and compared to Day 0 ]This is a first in HAM/TSP pilot study using teriflunomide thus important to monitor for any unexpected events related to worsening of clinical measures.
- Change in 25-foot timed walk [ Time Frame: at month 9 and compared to Day 0 ]This is a first in HAM/TSP pilot study using teriflunomide thus important to monitor for any unexpected events related to worsening of clinical measures.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- 18 years or older
- Diagnosis of HAM/TSP as defined by WHO criteria, including a positive HTLV-1 EIA and confirmatory Western Blot.
- Enrolled in 98-N-0047
- Patient must be willing and able to comply with all the aspects of trial design and follow-up.
- Negative QuantiFERON-TB gold, or completion of latent tuberculosis infection treatment, per CDC and National TB Controllers Association recommendations
- Ability to take oral medication and be willing to adhere to the protocol regimen
- Patients must be able to provide informed consent
- If able to become pregnant or to father a child, patient must agree to commit to the use of a reliable/accepted method of birth control (i.e. hormonal contraception (birth control pills, injected hormones, vaginal ring), intrauterine device, barrier methods with spermicide (diaphragm with spermicide, condom with spermicide) or surgical sterilization (hysterectomy, tubal ligation, or vasectomy) for the duration of the treatment arm of the study and for two years following cessation of treatment with teriflunomide.
An individual who meets any of the following criteria will be excluded from participation in this study:
- Alternative diagnoses that can explain neurological disability
- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial or interfere with participation for the full duration of the trial; or not in the best interest of the subject to participate, in the opinion of the treating investigator
- Severe immunodeficiency, bone marrow disease, or severe, uncontrolled infections.
- Liver dysfunction, as indicated by baseline aspartate aminotransferase (AST) or alanine or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal
- Positive serological evidence of HIV, HTLV II, Hepatitis B or C
- Treatment with immunomodulatory/immunosuppressive therapy (aside from topical steroids) in the preceding 6 months.
- Pregnant or lactating women.
- Treatment with other investigational drugs within 6 months before enrollment
- Known hypersensitivity to teriflunomide or leflunomide
- Concomitant treatment with leflunomide
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04799288
|Contact: Anita M Fletcher, M.D.||(301) email@example.com|
|Contact: Steven Jacobson, Ph.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Steven Jacobson, Ph.D.||National Institute of Neurological Disorders and Stroke (NINDS)|
|Responsible Party:||National Institute of Neurological Disorders and Stroke (NINDS)|
|Other Study ID Numbers:||
|First Posted:||March 16, 2021 Key Record Dates|
|Last Update Posted:||March 16, 2023|
|Last Verified:||March 13, 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||.All IPD that results in a publication|
Clinical Study Report (CSR)
|Time Frame:||6 months after publication|
|Access Criteria:||IPD will be shared under tech transfer agreements.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Paraparesis, Tropical Spastic
Spinal Cord Diseases
Nervous System Diseases
Central Nervous System Diseases
Central Nervous System Infections
RNA Virus Infections
Anti-Inflammatory Agents, Non-Steroidal
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs